Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmacists Must Play More Active Role in Promoting Use of Generics
December 10, 2007
- Industry Opposed to Re-Pricing of a Wider Range of Drugs
December 10, 2007
- JGPMA Accepted as Full Member of IGPA
December 10, 2007
- Another Reduction in Medical Fees Non Recommendable: Chuikyo
December 10, 2007
- Kobashou's Shareholders Approve Share Exchange with Mediceo
December 10, 2007
- Market Price Survey Shows Average Price Gap of 6.5%
December 10, 2007
- Taisho: Switch OTC Drug Containing Ambroxol Approved
December 10, 2007
- Janssen's Prezista Included in NHI Price List
December 10, 2007
- NEW PRODUCTS／SSP to Launch S.TAC EVE FINE
December 10, 2007
- Partial Changes in Approval for Xeloda, Taxol Recommended
December 10, 2007
- NIPRO to Pursue "Development-Oriented Contract Manufacturing Business"
December 10, 2007
- Five APIs Recommended for Approval by 1st Committee on Drugs
December 10, 2007
- MEDICAL DEVICE NEWS IN BRIEF
December 10, 2007
- Eisai Submits NDA for KES524 for Obesity
December 10, 2007
- Large Gap between Korosho and Council on Views on Kongo Shinryo
December 10, 2007
- Wyeth Submits 3rd NDA This Year
December 10, 2007
- Korosho to Set Up Group to Discuss Deregulations, Kongo Shinryo
December 10, 2007
- Astellas Aims at Becoming a Global Category Leader
December 10, 2007
- REGULATORY NEWS IN BRIEF
December 10, 2007
- Ban on Kongo Shinryo Should Be Lifted: Prof. Shimada
December 10, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…